NCT05434481

MITAORTA - Role of Mitochondrial Dynamic in Aneurysm and Dissection of Ascending Thoracic Aorta

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: University Hospital, Angers · Other Government
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Accepted

Summary

The main objective is to compare the mitochondrial dynamic between patients operated for aneurysm of ascending aorta or type A aortic dissection (AAD) or control group

Detailed description

In an aortic aneurysm process, the alteration of the extracellular matrix (ECM) as well as the apoptosis of the smooth muscle cells are due to inflammatory phenomena and oxydative stress, involving mitochondria which has a key place within cells. Mitochondrial fusion and fission constitute mitochondrial dynamic and are involved in the mechanisms described above. The alteration of mitochondrial dynamics has been demonstrated in many pathologies, in particular neurological, cancer and cardiovascular disease and generally occurs in favor of fission. In a mouse model (FASEB J, 2021, Robert P ), the role of mitochondrial fusion has been demostrated as a protective factor against hypertension in resistance arteries and a deletion of OPA1 (optic Atrophy 1) fusion protein may lead to aneurysm until aortic dissection. The results of this experimental study suggest a role of the alteration of mitochondrial dynamic in the development of aneurysm and aortic dissection.

Conditions

• Aortic Aneurysm and Dissection

Interventions

Type	Name	Description
OTHER	Mitochondrial dynamic analysis in the aorta samples and metabolomic profiling in the aortic diseases	* For each patient: a segment of aorta will be sampled and cutted into 4 parts * 1 fragment placed in a Falcon tube containing DMEM (Dulbecco's Modified Eagle Medium, Thermo Fisher®), temporarily stored at + 4°C, for primary culture of smooth muscle cells will allow analysis of the mitochondrial network. * 1 fragment placed in a Falcon tube containing Allprotect Tissue Reagent (QIAGEN®), stored at -80°C for gene (RT-PCR) and protein (Western Blot) analysis. * 2 fragments each placed in dry cryotube stored at - 80°C will be used for metabolomic analysis. * For each patient, 2 arterial blood samples will be collected before general anaesthesia * One tube of whole blood stored at -80°C for metabolomic analysis. * One tube of blood stored at -80°C for plasma cytokines

Timeline

• Start date: 2022-09-07
• Primary completion: 2023-10-23
• Completion: 2024-10-23
• First posted: 2022-06-28
• Last updated: 2024-06-11

Locations

1 site across 1 country: France